Children With Surgically Corrected Acyanotic Congenital Heart Disease (Pediatrics)

May 18, 2026 updated by: Delta University for Science and Technology

The goal of this quasi-experimental pretest-posttest controlled study is to learn whether moderate-intensity treadmill exercise can improve gait kinematics, walking capacity, and motor performance in preschool children aged 48-72 months with surgically corrected acyanotic congenital heart disease.

The main questions it aims to answer are:

Does moderate-intensity treadmill training improve gait kinematics, including stride length, walking speed, and double-stance percentage? Does moderate-intensity treadmill training improve walking capacity and balance in children with surgically corrected acyanotic congenital heart disease?

Researchers compared children with surgically corrected acyanotic congenital heart disease who received treadmill training with age-matched healthy children to see whether the exercise program could reduce gait, balance, and walking-capacity differences between the groups.

Participants with congenital heart disease completed:

Four treadmill walking sessions per week for 10 weeks. Moderate-intensity walking at approximately 70% of maximal heart rate. Pre- and post-intervention assessments of gait kinematics using three-dimensional motion analysis.

Balance assessment using the Pediatric Balance Scale. Walking capacity assessment using the six-minute walk test.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

80

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Egypt
      • Gamasa, Egypt, 35712
        • Amira Hussin Mohammed

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • For cyanotic postoperative congenital heart disease group:

    1. Children diagnosed with acyanotic postoperative congenital heart disease.
    2. Underwent surgical repair for CHD.
    3. Has a history of only one surgical intervention.
    4. Age between 48 and 72 months.

    5. Mentally normal, with an IQ between 85 and 115.

      For the healthy control group (HCG):

  • For healthy children aged 48 to 72 months. Full school attendance. Full participation in social and recreational activities. Parents/guardians provided written informed consent.

Exclusion Criteria:

Children were excluded if they had:

  1. Genetic disorders.
  2. Severe neurological disorders.
  3. Cyanotic congenital heart disease.
  4. Perinatal complications.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: congenital heart disease
The children in this group received walking sessions weekly for 10 weeks.
Other: treadmill walking sessions
4 sessions of walking on treadmill for 2.5 months
No Intervention: healthy group
health control group

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
gait parameters
Time Frame: basiline pre-test assessment and after 10 weeks of interventions (post-intervention assessment)
Gait parameters, including stride length (cm), speed (meters/minute), and double stance percentage (%) of the dominant leg, were assessed using a 3D motion analysis system.
basiline pre-test assessment and after 10 weeks of interventions (post-intervention assessment)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Delta University for Science and Technology

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

May 31, 2026

Primary Completion (Estimated)

August 31, 2026

Study Completion (Estimated)

September 1, 2026

Study Registration Dates

First Submitted

May 9, 2026

First Submitted That Met QC Criteria

May 18, 2026

First Posted (Actual)

May 26, 2026

Study Record Updates

Last Update Posted (Actual)

May 26, 2026

Last Update Submitted That Met QC Criteria

May 18, 2026

Last Verified

April 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • Acyanotic Heart Disease

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

All the required data that support the conclusion will be available when requested.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe